Lannett's deal call for another pharmaceutical company to purchase and distribute under a private label a limited number of certain other Lannett owned generic drug products.
Several pharmacy groups have filed a joint amicus brief stating that the Oklahoma Patient’s Right to Pharmacy Choice Act addresses a subset of the business practices of PBMs.
A new report by Beauty Pie and The Future Laboratory examines how consumers are now armed with greater access to product efficacy and supply chain efforts.